Interferon-stimulated Gene, 15 kDa (ISG15) in Ovarian High-grade Serous Carcinoma: Prognostic Impact and Link to NF-κB Pathway

International Journal of Gynecological Pathology

Volumn 33, Issue 1, 2014, Pages 16-22

  Darb Esfahani, Silvia ^a   Sinn, Bruno V ^a   Rudl, Marc ^a   Sehouli, Jalid ^b   Braicu, Ioana ^b   Dietel, Manfred ^a   Denkert, Carsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b Department of Gynecology ^*  (Germany)

Author keywords

High grade serous carcinoma; ISG15; NF kB; Ovarian; Prognosis

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ISG15 PROTEIN; ONCOPROTEIN; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; TREATMENT RESPONSE;

AGED; CYSTADENOCARCINOMA, SEROUS; CYTOKINES; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MIDDLE AGED; NEOPLASM GRADING; NF-KAPPA B; OVARIAN NEOPLASMS; PROGNOSIS; SIGNAL TRANSDUCTION; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; UBIQUITINS;

EID: 84890430045     PISSN: 02771691     EISSN: 15387151     Source Type: Journal    
DOI: 10.1097/PGP.0b013e31827b25a2     Document Type: Article

References (23)

1. Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.
2. Thigpen T, duBois A, McAlpine J, et al. First-line therapy in ovarian cancer trials. Int J Gynecol Cancer 2011;21:756-62.
3. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin 2012;62:10-29.
4. Vaughan S, Coward JI, Bast RC, Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;23:719-25.
5. Andersen JB, Hassel BA. The interferon regulated ubiquitinlike protein, ISG15, in tumorigenesis: friend or foe? Cytokine Growth Factor Rev 2006;17:411-21.
6. Siddoo-Atwal C, Haas AL, Rosin MP. Elevation of interferon beta-inducible proteins in ataxia telangiectasia cells. Cancer Res 1996;56:443-7.
7. Desai SD, Haas AL, Wood LM, et al. Elevated expression of ISG15 in tumor cells interferes with the ubiquitin/26S proteasome pathway. Cancer Res 2006;66:921-8.
8. Andersen JB, Aaboe M, Borden EC, et al. Stage-associated overexpression of the ubiquitin-like protein, ISG15, in bladder cancer. Br J Cancer 2006;94:1465-71.
9. Bektas N, Noetzel E, Veeck J, et al. The ubiquitin-like molecule interferon-stimulated gene 15 (ISG15) is a potential prognostic marker in human breast cancer. Breast Cancer Res 2008;10:R58.
10. Recht M, Borden EC, Knight E, Jr. A human 15-kDa IFNinduced protein induces the secretion of IFN-gamma. J Immunol 1991;147:2617-23.
11. D'Cunha J, Ramanujam S, Wagner RJ, et al. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 1996;157:4100-8.
12. Desai SD, Wood LM, Tsai YC, et al. ISG15 as a novel tumor biomarker for drug sensitivity. Mol Cancer Ther 2008;7: 1430-9.
13. Ina S, Hirono S, Noda T, et al. Identifying molecular markers for chemosensitivity to gemcitabine in pancreatic cancer: increased expression of interferon-stimulated gene 15 kd is associated with intrinsic chemoresistance. Pancreas 2010;39: 473-85.
14. Darb-Esfahani S, Sinn BV, Weichert W, et al. Expression of classical NF-kappaB pathway effectors in human ovarian carcinoma. Histopathology 2010;56:727-39.
15. McCluggage WG. My approach to and thoughts on the typing of ovarian carcinomas. J Clin Pathol 2008;61:152-63.
16. Tung CS, Mok SC, Tsang YT, et al. PAX2 expression in low malignant potential ovarian tumors and low-grade ovarian serous carcinomas. Mod Pathol 2009;22:1243-50.
17. Chiao PJ, Miyamoto S, Verma IM. Autoregulation of I kappa B alpha activity. Proc Natl Acad Sci USA 1994;91:28-32.
18. Minakawa M, Sone T, Takeuchi T, et al. Regulation of the nuclear factor (NF)-kappaB pathway by ISGylation. Biol Pharm Bull 2008;31:2223-7.
19. Nakanishi C, Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat Rev Cancer 2005; 5:297-309.
20. Liu M, Hummer BT, Li X, et al. Camptothecin induces the ubiquitin-like protein, ISG15, and enhances ISG15 conjugation in response to interferon. J Interferon Cytokine Res 2004;24:647-54.
21. Desai SD, Mao Y, Sun M, et al. Ubiquitin, SUMO-1, and UCRP in camptothecin sensitivity and resistance. Ann N Y Acad Sci 2000;922:306-8.
22. Burger RA, Brady MF, Bookman MA, et al. Gynecologic Oncology Group. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365: 2473-83.
23. Perren TJ, Swart AM, Pfisterer J, et al. ICON7 Investigators. A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365:2484-96.